Dan Wood is General Partner of Mesa Verde Venture Partners, an early-stage bioscience venture capital fund focused on the Southwestern United States. Prior to forming Mesa Verde in late 2006, Mr. Wood had been co-founding General Partner of IngleWood Ventures of San Diego in 1999. IngleWood had performed 13 bioscience company investments, primarily in very early-stage companies in San Diego County. Until 2007, Mr. Wood had served on the Board of Directors of CardioNet (NASDAQ-BEAT) for seven years and Cylene Pharmaceuticals for six years. Dan led the first institutional rounds of financing for these companies. He was also a Board Observer at Conforma Therapeutics (acquired by Biogen-Idec for $234 million) and Digirad (NASDAQ-DRAD). While at Mesa Verde, he was the first VC investor in Elevation Pharmaceuticals which was acquired by Sunovian for up to $430 million. Prior to forming IngleWood in 1999, he had served as president of the Sorrento Corporation, a registered investment advisory and publishing firm he formed in 1985 in San Diego. Mr. Wood is a Tufts University graduate and holds an MBA in Finance from the University of Connecticut and the Chartered Financial Analyst designation.